Search PubMed⌕ Search

Biomedical subjects

Y Mouton

Publications and source records attributed to Y Mouton.

At least 127 records · Page 7Linked to original sources
PubMed1986

[Effectiveness and tolerance of piperacillin in 333 patients].

In a French multicentric trial the effectiveness and safety of piperacillin were evaluated in 333 patients with severe infections. Piperacillin was administered alone in 212 cases. The overall results show that the drug was clinically effective in 85% of the patients. The results of this French study are similar to those of other studies previously published. They demonstrate an increase in the number of failures against ampicillin-resistant and carbenicillin-resistant strains, even when these strains were sensitive to piperacillin in vitro. Piperacillin was tolerated as well as the other beta-lactam antibiotics, the main side-effects being hypersensitivity reactions.

Anti-Bacterial Agents↗
PubMed1985

[Bronchial diffusion of piperacillin in 18 intensive care patients].

Eighteen patients (13 under mechanical ventilation) in an intensive care unit received piperacillin for pneumonia (7 cases) or bronchial infection (11 cases), related to Haemophilus influenzae (7), Streptococcus pneumoniae (4) or miscellaneous pathogens (7) including Staphylococcus, E. coli, Klebsiella pneumoniae and Proteus mirabilis. Each patient was given 2g piperacillin intravenously every six hours. Concentrations in serum and bronchial secretion samples were assayed by the agar diffusion technique using a susceptible strain of Bacillus subtilis ATCC 6633. Maximum concentrations were 157 micrograms/ml in serum and 3.60 micrograms/ml in bronchial secretions. These results are similar to those obtained with the same dosage by 0. Cars in serum (150 micrograms/ml) and by G.E. Marlin in the bronchial secretions (3.78 micrograms/ml). They approximate those published for other penicillins with the same dosage.

Bacterial Infections↗
PubMed1982

[Corynebacterium endocarditis. Diagnostic difficulties (author's transl)].

The authors report a case of endocarditis due to Corynebacterium diphtheriae. THe bacteriological study is difficult since this micro-organism can be undistinguishable from a saprophytic diphtheroid. The observed case is compared to previously published observations. All have in common the great severity of the illness, and the high mortality rate. Despite the clinical symptoms and the cerebrospinal fluid (CSF) abnormalities, meningitic involvement could not be demonstrated.

Adult↗
PubMed1982

[Pneumococcal septicemia: 145 cases (author's transl)].

Over a six year period, 145 pneumococcal septicemias were seen at the Tourcoing Hospital. This represents 0.39% of all hospitalized patients and 19.8% of all septicemias seen over the same period. A mortality rate of 38.6% was recorded. Prognostic factors were analyzed. The mortality rate was significantly higher in women (46.5%), in patients admitted for a reason unrelated to the septicemia (50.8%), and in patients with septic shock (81.5%) which was frequent (22.8%). An underlying poor general condition was present in 88.2% of the patients. This confirms the high risk of pneumococcal infections in some patients who should be protected by vaccination.

Adolescent↗
PubMed1982

[Treatment of septicemia with latamoxef. Multicentric study of 60 cases].

Sixty patients including forty two males and eighteen females, age range: 18-87 years, received antibacterial single drug treatment with latamoxef for septicemia. Forty nine patients had underlying conditions including multiple trauma, neoplasm, cardiovascular, metabolic and respiratory tract diseases. Causative pathogens were isolated in all cases. The predominant isolates were E. coli (thirty), Klebsiella pneumoniae (tent) and Enterobacter (seven). A single organism was isolated in fifty seven cases; in the other three cases two organisms were isolated from blood cultures. Mean daily dosage was 46.6 +/- 6.1 mg . kg-1 (range: 14-113 mg . kg-1). In the majority of cases (fifty two) dosage was 3 g . d-1 or less; in thirty cases it was no higher than 2 g . d-1. Duration of therapy ranged from six to thirty eight days. Serum titer was measured in many cases and latamoxef blood levels were assayed in nine patients. A satisfactory clinical response was achieved in fifty eight cases and fifty eight bacteriological cures were also obtained. There was no statistically significant difference in therapeutic response between the 2 g and 3 g daily dosage groups. Tolerance was very good; untoward effects were few and required drug discontinuation in one case only.

Adolescent↗
PubMed1982

[Use of moxalactam in intensive care units: clinical and bacteriological results related to serum and bronchial concentrations ].

Twenty-patients (14 with mechanical ventilation) received moxalactam in an intensive care unit for pneumonia (3 cases), empyema (5 cases), bronchopneumonia (8 cases), bronchopneumonia with bacteremia (4 cases), 23 organism were isolated and 16 were hospital-acquired: Staphylococcus (3), Escherichia coli (1), Klebsiella-Enterobacter-Serratia (5), Proteus (3), Aeruginosa (2), Acinetobacter (2), These patients received moxalactam at the dosage of 500 mg/8H, 5 at 1 g/12H and 13 at 1 g/8H. Daily dosage ranged between 25 and 50 mg/kg; mode of administration was IM (16) or IV infusion pump (5) and mean duration of treatment was 12 days (range 6-21). Serum and bronchial secretion samples were assayed by the agar diffusion technique utilizing a susceptible strain of enterobacter cloacae (0.06 microgram/ml) as assay organism. At 1 h, mean serum concentrations were 31.5 micrograms/ml after 1 g IM every 12H, 54.9 micrograms/ml after 1 g IM every 8H and at 30 mn after the end of the infusion, serum concentrations were 54.2 micrograms/ml. At the same time, bronchial secretion concentrations were respectively 2.1 micrograms/ml, 5 micrograms/ml and 3.7 micrograms/ml. Clinical cures were obtained in 16 (80%) and bacteriological cures occurred in 14 (70%); of the 12 hospital - acquired infections patients, 8 experienced clinical cures (66%) and the emergence of the following organisms was observed during moxalactam treatment: Staphylococcus (1), Enterococcus (1), Pseudomonas aeruginosa (1), Acinetobacter (3), For the 20 patients, we noted 4 adverse effects: pruritic morbilliform eruption (1), thrombocytosis (1), eosinophilia (2), To avoid failures, the usefulness of routine combinations with amyglycosides is discussed for the cases of hospital - acquired infections.

Adult↗